Search Results - "Mauer, M"

Nuclear genome annotation of wheel animals and thorny-headed worms: inferences about the last common ancestor of Syndermata (Rotifera s.l.) by Hagemann, Laura, Mauer, Katharina M., Hankeln, Thomas, Schmidt, Hanno, Herlyn, Holger

“…The basal splits within Syndermata probably date back hundreds of millions of years, and extant syndermatans greatly differ in reproduction modes…”
Get full text

Gender medicine and oncology: report and consensus of an ESMO workshop by Wagner, A.D., Oertelt-Prigione, S., Adjei, A., Buclin, T., Cristina, V., Csajka, C., Coukos, G., Dafni, U., Dotto, G.-P., Ducreux, M., Fellay, J., Haanen, J., Hocquelet, A., Klinge, I., Lemmens, V., Letsch, A., Mauer, M., Moehler, M., Peters, S., Özdemir, B.C.

“…The importance of sex and gender as modulators of disease biology and treatment outcomes is well known in other disciplines of medicine, such as cardiology,…”
Get full text

kidney in diabetes: dynamic pathways of injury and repair. The Camillo Golgi Lecture 2007 by Fioretto, P, Caramori, M. L, Mauer, M

“…Diabetic nephropathy is the most common cause of end-stage renal disease (ESRD). The natural history of diabetic nephropathy has changed over the last decades,…”
Get full text

Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983 by Tanis, E, Nordlinger, B, Mauer, M, Sorbye, H, van Coevorden, F, Gruenberger, T, Schlag, P.M, Punt, C.J.A, Ledermann, J, Ruers, T.J.M

“…Abstract Aim The aim of this study is to describe local tumour control after radiofrequency ablation (RFA) and surgical resection (RES) of colorectal liver…”
Get full text

Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004) by Ruers, T., Punt, C., Van Coevorden, F., Pierie, J.P.E.N., Borel-Rinkes, I., Ledermann, J.A., Poston, G., Bechstein, W., Lentz, M.A., Mauer, M., Van Cutsem, E., Lutz, M.P., Nordlinger, B.

“…This study investigates the possible benefits of radiofrequency ablation (RFA) in patients with non-resectable colorectal liver metastases. This phase II…”
Get full text

Identity: Key to Children's Understanding of Belief by Perner, Josef, Mauer, M. Christine, Hildenbrand, Monika

“…Is knowledge structured and acquired as independent facts and concepts, as parcels of independent domains, or as domains that share conceptual abilities? For…”
Get full text

Genomics and transcriptomics of epizoic Seisonidea (Rotifera, syn. Syndermata) reveal strain formation and gradual gene loss with growing ties to the host by Mauer, Katharina M, Schmidt, Hanno, Dittrich, Marco, Fröbius, Andreas C, Hellmann, Sören Lukas, Zischler, Hans, Hankeln, Thomas, Herlyn, Holger

“…Abstract Background Seisonidea (also Seisonacea or Seisonidae) is a group of small animals living on marine crustaceans ( Nebalia spec.) with only four species…”
Get full text

Glomerular structural-functional relationship models of diabetic nephropathy are robust in type 1 diabetic patients by Mauer, Michael, Caramori, Maria Luiza, Fioretto, Paola, Najafian, Behzad

“…Studies of structural-functional relationships have improved understanding of the natural history of diabetic nephropathy (DN). However, in order to consider…”
Get full text

Eicosanoid Modulation in Advanced Lung Cancer: Cyclooxygenase-2 Expression Is a Positive Predictive Factor for Celecoxib + Chemotherapy—Cancer and Leukemia Group B Trial 30203 by EDELMAN, Martin J, WATSON, Dee, BEDOR, Michelle, VOKES, Everett E, GREEN, Mark J, XIAOFEI WANG, MORRISON, Carl, KRATZKE, Robert A, JEWELL, Scott, HODGSON, Lydia, MAUER, Ann M, GAJRA, Ajeet, MASTERS, Gregory A

“…Increased expression of eicosanoids in cancer has been associated with adverse prognosis. We performed a randomized phase II trial to test the hypothesis that…”
Get full text

The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? by CARAMORI, M. L, FIORETTO, P, MAUER, M

“…The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? M L Caramori , P Fioretto and M Mauer Department of…”
Get full text

Phase II Trial of Gefitinib 250 mg Daily in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck by COHEN, Ezra E. W, KANE, Madeleine A, LIST, Marcy A, BROCKSTEIN, Bruce E, MEHROTRA, Bhoomi, DEZHENG HUO, MAUER, Ann M, PIERCE, Carolyn, DEKKER, Allison, VOKES, Everett E

“…Purpose: An objective response rate of 11% was reported in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN)…”
Get full text

Terminal complement complex formation is associated with intervertebral disc degeneration by Teixeira, Graciosa Q., Yong, Zhiyao, Goncalves, Raquel M., Kuhn, Amelie, Riegger, Jana, Brisby, Helena, Barreto Henriksson, Helena, Ruf, Michael, Nerlich, Andreas, Mauer, Uwe M., Ignatius, Anita, Brenner, Rolf E., Neidlinger-Wilke, Cornelia

“…Purpose The complement system is a crucial part of innate immunity. Recent work demonstrated an unexpected contribution to tissue homeostasis and degeneration…”
Get full text

Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation by WARNOCK, David G, ORTIZ, Alberto, LEMAY, Roberta, COLE, J. Alexander, SVARSTAD, Einar, WALDEK, Stephen, GERMAIN, Dominique P, WANNER, Christoph, MAUER, Michael, LINTHORST, Gabor E, OLIVEIRA, Joao P, SERRA, Andreas L, MARODI, László, MIGNANI, Renzo, VUJKOVAC, Bojan, BEITNER-JOHNSON, Dana

“…The purpose of this study was to identify determinants of renal disease progression in adults with Fabry disease during treatment with agalsidase beta. Renal…”
Get full text

New strategies and designs in pancreatic cancer research: consensus guidelines report from a European expert panel by Van Laethem, J.-L., Verslype, C., Iovanna, J.L., Michl, P., Conroy, T., Louvet, C., Hammel, P., Mitry, E., Ducreux, M., Maraculla, T., Uhl, W., Van Tienhoven, G., Bachet, J.B., Maréchal, R., Hendlisz, A., Bali, M., Demetter, P., Ulrich, F., Aust, D., Luttges, J., Peeters, M., Mauer, M., Roth, A., Neoptolemos, J.P., Lutz, M.

“…Although the treatment of pancreatic ductal adenocarcinoma (PDAC) remains a huge challenge, it is entering a new era with the development of new strategies and…”
Get full text

Remodeling of renal interstitial and tubular lesions in pancreas transplant recipients by Fioretto, P., Sutherland, D.E.R., Najafian, B., Mauer, M.

“…Tubular atrophy and interstitial fibrosis, important in progression of renal diseases, including diabetic (D) and cyclosporine-induced (CSA) nephropathy, have…”
Get full text

Predicting decline of kidney function in lupus nephritis using urine biomarkers by Abulaban, K M, Song, H, Zhang, X, Kimmel, P L, Kusek, J W, Nelson, R G, Feldman, H I, Vasan, R S, Ying, J, Mauer, M, Nelsestuen, G L, Bennett, M, Brunner, H I, Rovin, B H

“…Objective To evaluate candidate biomarkers to predict future renal function decline (RFD) in children and adults with lupus nephritis (LN). Methods At the time…”
Get full text

Standardising clinical outcomes measures for adult clinical trials in Fabry disease: A global Delphi consensus by Moreno-Martinez, D., Aguiar, P., Auray-Blais, C., Beck, M., Bichet, D.G., Burlina, A., Cole, D., Elliott, P., Feldt-Rasmussen, U., Feriozzi, S., Fletcher, J., Giugliani, R., Jovanovic, A., Kampmann, C., Langeveld, M., Lidove, O., Linhart, A., Mauer, M., Moon, J.C., Muir, A., Nowak, A., Oliveira, J.P., Ortiz, A., Pintos-Morell, G., Politei, J., Rozenfeld, P., Schiffmann, R., Svarstad, E., Talbot, A.S., Thomas, M., Tøndel, C., Warnock, D., West, M.L., Hughes, D.A.

“…Recent years have witnessed a considerable increase in clinical trials of new investigational agents for Fabry disease (FD). Several trials investigating…”
Get full text

Adaptive designs at European Organisation for Research and Treatment of Cancer (EORTC) with a focus on adaptive sample size re-estimation based on interim-effect size by Mauer, M, Collette, L, Bogaerts, J

“…Abstract Given the high failure rates and the increased costs of Phase III trials in oncology and the recent explosion of targeted agents, researchers are…”
Get full text

Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971 TAX 323) by van Herpen, C M L, Mauer, M E, Mesia, R, Degardin, M, Jelic, S, Coens, C, Betka, J, Bernier, J, Remenar, E, Stewart, J S, Preiss, J H, van den Weyngaert, D, Bottomley, A, Vermorken, J B

“…Background: The EORTC 24971/TAX 323, a phase III study of 358 patients with unresectable locoregionally advanced squamous cell carcinoma of the head and neck,…”
Get full text

EORTC stomach cancer PD-L1 biomarker European initiative: the ASPIRE study protocol by A. Petrillo, L. Oudijk, R. Sundar, C. Daumer, J. Casas, D. D’Haese, M. Mauer, N. van Grieken, E.C. Smyth, M. Moehler

“…The evaluation of programmed death-ligand 1 (PD-L1) expression and the methodology employed are central to identify suitable candidates for immunotherapy among…”
Get full text